サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1316304

セラノスティクスの世界市場-2023年～2030年

Global Theranostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
セラノスティクスの世界市場-2023年～2030年
出版日: 2023年07月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のセラノスティクス市場は、2022年に18億米ドルに達し、2030年には42億米ドルに達する好成長が見込まれています。世界のセラノスティクス市場は、予測期間中（2023-2030年）に11.3%のCAGRを示す見込みです。

セラノスティクスとは、治療学と診断学を組み合わせた言葉です。セラノスティクスとは、1つの放射性薬剤を使用して同定（診断）し、2つ目の放射性薬剤を使用して治療を行い、主腫瘍と転移性腫瘍を治療する組み合わせを表す用語です。これらの検査は、主に様々ながんに用いられています。治療における重要な関心事は、より個別化された正確なアプローチによる患者中心の治療です。

世界のセラノスティクス市場の最近の動向には、イメージング能力を持つナノ医薬品の広範な採用や、診断と薬物療法を組み合わせたナノセラノスティクスとして知られる単一事業体への統合が含まれます。さらに、細菌のセラノスティクスに凝集誘導発光体を使用することへの関心が高まっています。

同市場では、製薬会社、研究機関、医療提供者の間で投資や共同研究が活発化しています。この背景には、個別化された標的治療を提供するセラノスティクスに対する需要の増加があります。さらに、セラノスティクス分野における継続的な研究努力、臨床試験数の増加、認知度の向上と進歩の促進を目的とした学会数の増加が、予測期間を通じて主要な促進要因になると予想されます。

市場力学

がん管理のための放射性核種セラノスティクスの調査会議の増加がセラノスティクスの世界市場の成長を促進

Gordon Research Conference 2022によると、がん患者の管理における放射性核種セラノスティクスの最新の進歩と影響について調査します。この会議は、科学者、医師、学界、民間診療所、産業界など様々な分野の専門家を含む著名な講演者グループ間の公式・非公式な交流と協力を促進することを目的としています。この会議の科学的な1次調査の目的は、放射性核種によるセラノスティクスに関連する課題に取り組み、がん研究における大きなブレークスルーを促すことです。

小規模で人目につかない環境、未発表のデータ、十分な討論時間を特徴とするこの会議のユニークな形式は、この分野に実質的かつ永続的な影響を与える可能性の高い有意義な交流や共同研究のための特別な機会を提供します。放射性核種を用いた画像診断と治療を利用した精密腫瘍学が、技術革新と著しい成長という変革期を迎えている今、この集まりは特に重要です。

それは、これまで以上に精密な診断と、個別化された効果的な抗腫瘍治療の可能性を提供するものです。さらにこのことは、大手製薬会社の参入が増加し、放射線腫瘍学分野で50を超える新規参入企業が出現していることからも明らかです。

さらに、ベータ線、アルファ線、ガンマ線を放出する放射性核種をがん治療に利用する臨床試験の数も急速に拡大しています。この会議が開催されるタイミングは、放射性核種を用いたプレシジョン・オンコロジーが大きく前進し、この分野のパラダイムシフトと前例のない進歩を意味する極めて重要な瞬間に重なるため、極めて重要です。このように、上記の要因により、予測期間中、市場は牽引役となると思われます。

がんにおけるFDA承認の増加がセラノスティクスの世界市場の成長を牽引

2022年11月29日、Clarity Pharmaceuticalsは、FDAから前立腺がん治療薬SAR-Bombesinの臨床試験実施の承認を取得しました。前立腺がんは、世界的にがん関連死因の第5位にランクされ、男性で2番目に多く診断されるがんです。NCIによると、米国だけでも年間約268,490例の前立腺がんが報告され、約34,500人が死亡しています。

SAR-Bombesinは、様々なタイプのがんに存在する特定の細胞表面レセプターを標的とするように設計された放射性医薬品です。プレスリリースでは、ガストリン放出ペプチド受容体（GRPr）が前立腺がんの75-100％に存在することを強調しています。

SAR-Bombesin化合物には複数の利点があります。SARの成分はサルコファジンとして知られ、銅同位体を安全にカプセル化するキレーターとして働き、体内への漏出を防ぐ。同社によれば、SAR-ボンベシンは標的銅セラノシス（TCT）であり、イメージング目的には銅64同位体（Cu-64または64Cu）を、治療用途には銅67同位体（Cu-67または67Cu）を利用できます。

同様に、2022年3月23日、ノバルティスは177Lu-PSMA-617として知られていたPluvictoTM（lutetium Lu 177 vipivotide tetraxetan）のFDA承認を取得しました。この承認により、Pluvictoは、前立腺特異的膜抗原陽性（PSMA陽性）腫瘍が体の他の部位に転移している転移性去勢抵抗性前立腺がん（mCRPC）の成人患者の治療に使用できます。これらの患者は、アンドロゲン受容体経路阻害やタキサン系化学療法などの他の抗がん剤治療を既に受けています。

さらに、FDAはLocametz（ガリウムGa68ゴゼトチド注射液調製用キット）を承認しました。放射性同位元素標識後、このイメージング薬剤をmCRPC成人患者に使用し、ポジトロン断層撮影（PET）スキャンによりPSMA陽性病変を同定することができます。

ガリウム-68標識Locametzを使用することで、医師はPSMAバイオマーカーを発現する腫瘍病変を検出し、軟部組織、リンパ節、骨など体内の腫瘍の広がりを判定することができます。これは、Pluvictoによる標的治療の対象となる患者を特定するのに役立ちます。PSMAは前立腺がん患者の80％以上で高発現しており、転移性前立腺がんの進行度を評価する上で極めて重要なバイオマーカーとなっています。

セラノスティクスの高コストが世界のセラノスティクス市場の成長を妨げる

放射性医薬品を利用するセラノスティクスの分野は、がんの診断と治療を改善する上で大きな可能性を秘めています。しかし、最も効果的な放射性医薬品の中には、入手が困難で、がん細胞を標的として排除できる薬剤に変換するのにコストがかかる希少同位元素に依存しているものもあります。がん治療の進歩は間近に迫っているが、それには必然的に高額な費用がかかります。

例えば、がん診断のためのルテチウム177療法の費用は、国、病院、治療する医師によって異なります。ルテチウム177療法の平均的な費用は1コースあたり約1万米ドルで、患者は3～4コース受けることになります。

COVID-19影響分析

セラノスティクス市場は、COVID-19の発生による影響により、予測期間中に初期課題と衰退に直面することになります。全国的な封鎖と規制により、診断サービスの中断や処置のキャンセルが発生し、セラノスティクスの需要に影響を及ぼしています。

パンデミックは、年齢や併存疾患により重症化のリスクが高い腫瘍や心血管疾患の患者のケアに特に影響を及ぼしています。パンデミックの規模や規制は地域によって異なり、慢性疾患患者への影響もさまざまです。

ドイツのような国では、ヘルスケアシステムへの負担を防ぐための努力がなされたが、公共の場での戸締まりや緊急性のない医療サービスへのアクセス制限が実施されました。ヘルスケア業界は、COVID-19のためにサプライチェーンと需要の混乱を経験しました。

COVID-19を含む感染症の病原性を低下させるのに役立つセラノスティクスは、一般市民の病院受診への恐怖が、腫瘍学や腫瘍関連疾患で一般的に使用されるセラノスティクス処置の需要を鈍化させたため、影響を受けています。しかし、パンデミックが制圧され、人々が新しいライフスタイルに適応するにつれて、医療専門家たちはウイルスを研究し、その治療におけるセラノスティクスの使用を模索しています。

COVID-19パンデミックの世界の影響から、ウイルスの蔓延を緩和し、効率的な治療薬を開発するために、より効果的な対策を実施する必要があります。コロナウイルスを含むウイルスの高い不均一性は、効果的な抗ウイルス剤を開発する上で大きな課題となります。ウイルスの高い変異率は、ウイルスの検出、薬剤やワクチン開発の効果に悪影響を及ぼし、薬剤耐性につながることさえあります。しかし、セラノスティクスの分野は有望な解決策を提供しています。

さらに、ナノロボットの使用はウイルスからのリアルタイム防御を提供し、COVID-19を含む様々な疾患に対するセラノスティクスの大幅な進歩の可能性を開く。さらに、ナノテクノロジーに基づくアプローチは、従来の消毒手順に革命をもたらすだけでなく、コロナウイルスとそれに関連するバイオマーカーの加速モニタリングのための分析ツールも提供します。これらのアプローチは、呼吸器系やその他の罹患臓器へのドラッグデリバリーを促進することができます。

ロシア・ウクライナ紛争分析

ロシアとウクライナの戦争は、セラノスティクス市場への潜在的な影響を含め、世界の地政学的状況の様々な側面に影響を与えています。政情不安の中、ロシア、ウクライナ、その他の国々の研究機関間の研究開発協力は課題に直面する可能性があります。科学的協力関係の混乱は、セラノスティック研究の進展を遅らせ、新技術や治療法の開発を妨げる可能性があります。

現在進行中の紛争は、ロシアとウクライナの両国のヘルスケア・システムにさらなる負担をかける可能性があります。紛争から生じる緊急のヘルスケアニーズへの対応に資源が振り向けられるため、セラノスティクスの研究、インフラ、実施への投資や優先順位が影響を受ける可能性があります。したがって、先に述べた要因を考慮すると、セラノスティクス市場は戦争の結果として中程度の影響を受けたと言えます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • がん管理のための放射性核種セラノスティクスの研究会議の増加
      • がんにおけるFDA承認の増加
    • 抑制要因
      • セラノスティックス診断の高コスト
    • 機会
      • 光駆動型セラノスティクスの急成長分野
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 用途別

  • 腫瘍学
  • 神経疾患
  • 心血管疾患
  • その他

第9章 放射性同位元素別

  • テクネチウム-99
  • ガリウム-68
  • ルテチウム（Lu）177
  • ヨウ素131
  • ジルコニウム-89
  • Y-90
  • その他

第10章 エンドユーザー別

  • 病院
  • がん研究機関
  • 診断センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第13章 企業プロファイル

  • GE Healthcare
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Jubilant Pharmova Limited（Jubilant Pharma Limited）
  • Theragnostics Ltd.
  • NuView Life Sciences
  • Lantheus Holdings, Inc.
  • CapVest Limited（Curium Pharma）
  • Clarity Pharmaceuticals
  • Cardinal Health, LLC
  • Advanced Accelerator Applications
  • ITM Isotopen Technologien Munchen AG

第14章 付録

目次
Product Code: BT1187

Market Overview

The global theranostics market reached US$ 1.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 4.2 billion by 2030. The global theranostics market is to exhibit a CAGR of 11.3% during the forecast period (2023-2030).

Theranostics is a combination of the terms therapeutics and diagnostics. Theranostics is the term used to describe the combination of using one radioactive drug to identify (diagnose) and a second radioactive drug to deliver therapy to treat the main tumor and any metastatic tumors. These tests are mainly used for various forms of cancers. The key concern in therapeutics involves patient-centric care with the help of a more personalized and precise approach.

Recent trends in the global theranostics market include the widespread adoption of nanomedicines for their imaging capabilities and their integration into a single entity known as nanotheranostics, which combines diagnosis and drug therapy. Additionally, there is a growing interest in using aggregation-induced emissive luminogens for bacterial theranostics.

The market is witnessing rising investment and collaborations among pharmaceutical companies, research institutions, and healthcare providers. This is driven by the increasing demand for theranostics, which offer personalized and targeted treatments. Furthermore, ongoing research endeavors in the field of theranostics, a rise in the number of clinical trials, and the increasing number of conferences aimed at raising awareness and promoting advancements are anticipated to be key driving factors throughout the forecast period.

Market Dynamics

Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer are to Drive Global Theranostics Market Growth

According to Gordon Research Conference 2022, it will explore the latest advancements and impact of Radionuclide Theranostics in the management of cancer patients. It aims to facilitate formal and informal interactions and collaborations among a distinguished group of speakers, including scientists, physicians, and experts from various sectors such as academia, private practice, and industry. The primary scientific objective of the conference is to address the challenges associated with radionuclide theranostics and encourage significant breakthroughs in cancer research.

The unique format of the conference, characterized by its small size, secluded setting, unpublished data, and ample time for discussion, provides an exceptional opportunity for meaningful interactions and collaborations that are likely to have a substantial and enduring impact on the field. This gathering is particularly significant as precision oncology utilizing radionuclide-based imaging and therapy is experiencing a transformative phase of innovation and remarkable growth.

It offers the potential for more precise diagnostics and personalized and effective anti-tumor treatments than ever before. Moreover, this is evident from the increasing participation of major pharmaceutical companies and the emergence of over 50 new players in the field of radiotheranostics.

Furthermore, the number of clinical trials utilizing beta, alpha, or gamma-emitting radionuclides in cancer treatment is rapidly expanding. The timing of this conference is crucial, as it coincides with the pivotal moment when radionuclide-based precision oncology is poised for significant advancements, signifying a paradigm shift in the field and unprecedented progress. Thus, owing to the above factors, the market is to drive over the forecast period.

Increasing FDA Approvals in Cancer are to Drive Global Theranostics Market Growth

On November 29, 2022, Clarity Pharmaceuticals received approval from the FDA to conduct clinical trials with SAR-Bombesin, a theranostic agent, for the treatment of prostate cancer. Prostate cancer ranks as the fifth leading cause of cancer-related deaths worldwide and is the second most commonly diagnosed cancer in men. In the United States alone, approximately 268,490 cases of prostate cancer are reported annually, resulting in about 34,500 deaths, according to the NCI.

SAR-Bombesin is a radiopharmaceutical designed to target specific cell surface receptors present in various types of cancer. The press release highlights that gastrin-releasing peptide receptors (GRPr) can be found in 75-100% of prostate cancers.

The SAR-Bombesin compound offers multiple benefits. Its SAR component, also known as sarcophagine, acts as a chelator that securely encapsulates copper isotopes, preventing any leakage into the body. The company states SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can utilize copper-64 isotopes (Cu-64 or 64Cu) for imaging purposes and copper-67 isotopes (Cu-67 or 67Cu) for therapeutic applications.

Similarly, on March 23, 2022, Novartis received FDA approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), previously known as 177Lu-PSMA-617. This approval allows Pluvicto to be used in the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have prostate-specific membrane antigen-positive (PSMA-positive) tumors that have spread to other parts of the body. These patients have already undergone other anticancer treatments such as androgen receptor pathway inhibition and taxane-based chemotherapy.

Additionally, the FDA has approved Locametz (kit for the preparation of gallium Ga 68 gozetotide injection). After radiolabeling, this imaging agent can be used in adult patients with mCRPC to identify PSMA-positive lesions through positron emission tomography (PET) scans.

By using Gallium-68 labeled Locametz, physicians can detect tumor lesions expressing the PSMA biomarker and determine the spread of tumors in the body, including soft tissue, lymph nodes, or bone. This helps identify patients eligible for targeted treatment with Pluvicto. PSMA is highly expressed in over 80 percent of patients with prostate cancer, making it a crucial biomarker for assessing the progression of metastatic prostate cancer.

High Cost of Theranostics is to Hamper Global Theranostics Market Growth

The field of theranostics, which utilizes radiopharmaceuticals, holds great promise for improving cancer diagnosis and treatment. However, some of the most effective theranostic agents rely on rare isotopes that are challenging to obtain and costly to convert into drugs capable of targeting and eliminating cancer cells. While advancements in cancer care are shortly, they will inevitably come with a high price tag.

For instance, the cost of Lutetium-177 therapy for cancer diagnosis varies depending on the country, hospital, and treating doctor. The average cost of Lutetium-177 therapy is around $10,000 per course, and a patient may undergo three to four courses.

Similarly, in India, the estimated cost of Lu177 PSMA Therapy usually starts at $5000 and may go up to $6000. Also, in Germany, the cost of PSMA therapy with Lutetium 177 in specialized hospitals ranges between 8000-16,000 euros, which covers the cost of the initial clinical and laboratory examination, the PSMA therapy itself, the follow-up examinations, and the hospital stay. Thus, owing to the above factors, the market is to hamper over the forecast period.

COVID-19 Impact Analysis

The theranostics market is to face initial challenges and decline during the forecast period due to the impact of the COVID-19 outbreak. Nationwide lockdowns and restrictions have led to disrupted diagnostic services and canceled procedures, affecting the demand for theranostics.

The pandemic has particularly affected the care of patients with oncology and cardiovascular diseases, as they are at a higher risk of severe illness due to their age and comorbidities. The extent of the outbreak and the restrictions imposed vary across regions, influencing individuals with chronic diseases differently.

In countries like Germany, efforts were made to prevent strain on the healthcare system, but public lockdowns and limited access to non-urgent medical services were implemented. The healthcare industry has experienced disruptions in supply chains and demand due to COVID-19.

Theranostics, which can assist in reducing the virulence of infections, including COVID-19, have been impacted as the fear of hospital visits among the public has slowed down the demand for theranostic procedures, which are commonly used in oncology and tumor-related conditions. However, as the pandemic is brought under control and people adapt to the new lifestyle, medical experts have been studying the virus and exploring the use of theranostics in its treatment.

The global impact of the COVID-19 pandemic necessitates the implementation of more effective measures to mitigate the spread of the virus and develop efficient theranostic agents. The high heterogeneity of viruses, including the coronavirus, poses a significant challenge in developing effective antiviral agents. The virus's high mutation rates can negatively impact virus detection, the efficacy of drug and vaccine development, and even lead to drug resistance. However, the field of theranostics offers promising solutions.

Additionally, the use of nanorobots provides real-time protection against viruses, opening up possibilities for significant advancements in theranostics for various diseases, including COVID-19. Furthermore, nanotechnology-based approaches not only revolutionize traditional disinfection procedures but also offer analytical tools for accelerated monitoring of the coronavirus and its associated biomarkers. These approaches can facilitate drug delivery to the respiratory system or other affected organs.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had an impact on various aspects of the global geopolitical landscape, including potential implications for the theranostics market. In the face of political instability, research and development collaborations between institutions in Russia, Ukraine, and other countries may face challenges. Disruptions in scientific collaborations could slow down the progress of theranostic research and hinder the development of new technologies and treatments.

The ongoing conflict may place additional strain on the healthcare systems in both Russia and Ukraine. As resources are redirected towards addressing immediate healthcare needs arising from the conflict, investments, and priorities for theranostics research, infrastructure, and implementation may be affected. Therefore, taking into account the factors mentioned earlier, it can be stated that the theranostics market experienced a moderate impact as a result of the war.

Segment Analysis

The global theranostics market is segmented based on application, radioisotopes, end user, and region.

Oncology from the Application Segment Account for 57.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Growing Theranostics Gordon Research Conferences

According to Pan American Health Organization Report 2023, globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with the greatest increases occurring in low- and middle-income countries.

In the Americas region the, number of people to be diagnosed with cancer will increase by 57%, to approximately 6.23 million people are predicted to be diagnosed with cancer by 2040, if no further action is taken to prevent and control cancer.

Additionally, On June 23, 2023, Cardinal Health Nuclear & Precision Health Solutions (NPHS) will be showcasing their radiotherapies and theranostics readiness at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in booth #2041.

Attendees at the Cardinal Health NPHS booth will have the opportunity to learn about the company's reliable access to radiopharmaceuticals and solutions that contribute to safe, efficient, and high-quality patient care. The booth will feature demonstrations of the Nuctrac theranostic module and offer "Ask an Expert" sessions on theranostics and USP <825>, which sets requirements for the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals.

At SNMMI 2023, visitors to Booth #2041 will discover how Cardinal Health NPHS is advancing nuclear medicine through its expertise and comprehensive range of products and services. They are dedicated to improving patient care by enhancing productivity, efficiency, and theranostics practice management solutions. Thus, owing to the above factors, the market segment is to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 43.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Rising FDA Approvals, and Growing Research in Theranostics

The increasing prevalence of cancer, rising FDA approvals, and growing research in theranostics are some factors due to which the market is to boost in the forecast period. For instance, on March 23, 2022, the U.S. FDA approved 177Lu-PSMA-617, a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC). In mCRPC patients treated with 177Lu-PSMA-617, the therapy has been shown to reduce the risk of death by 38% and the risk of progression by 60%. It was developed after years of extensive research.

Furthermore, UChicago Medicine is a leader in the development and administration of theranostic procedures. They are actively researching to expand this promising treatment option for other types of cancer. UChicago Medicine is the only hospital in Illinois to have a medical cyclotron, which is a powerful machine capable of manufacturing new kinds of radiotracers. The research team partners with experts at Argonne National Laboratory, an internationally renowned facility that has provided instrumental research on using radiation to treat cancer.

Sophisticated radiotracers consisting of a biological component engineered to latch on to cancer cells and interchangeable radioactive isotopes that can make those cells visible on a PET scan are providing physicians with more tools to fight certain cancers. Theranostics is a one-two punch against cancer that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells. Thus, owing to the above factors, the North American region is to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: GE Healthcare, Jubilant Pharmova Limited (Jubilant Pharma Limited), Theragnostics Ltd., NuView Life Sciences, Lantheus Holdings, Inc., CapVest Limited (Curium Pharma), Clarity Pharmaceuticals, Cardinal Health, LLC, Advanced Accelerator Applications, and ITM Isotopen Technologien Munchen AG among others.

Why Purchase the Report?

  • To visualize the global theranostics market segmentation based on application, radioisotopes, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of theranostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global theranostics market report would provide approximately 61 tables, 63 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Application
  • 3.2. Snippet by Radioisotopes
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer
      • 4.1.1.2. Increasing FDA Approvals in Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Theranostics Diagnostic
    • 4.1.3. Opportunity
      • 4.1.3.1. Fast-Growing Field of Photo-Driven Theranostics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Oncology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Neurological Disorder
  • 8.4. Cardiovascular Disease
  • 8.5. Others

9. By Radioisotopes

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 9.1.2. Market Attractiveness Index, By Radioisotopes
  • 9.2. Technetium-99*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Gallium-68
  • 9.4. Lutetium (Lu) 177
  • 9.5. Iodine-131
  • 9.6. Zirconium-89
  • 9.7. Y-90
  • 9.8. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Cancer Research Institutes
  • 10.4. Diagnostic Centers
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.6.1. U.S.
      • 11.2.6.2. Canada
      • 11.2.6.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.6.1. Germany
      • 11.3.6.2. U.K.
      • 11.3.6.3. France
      • 11.3.6.4. Italy
      • 11.3.6.5. Spain
      • 11.3.6.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.6.1. Brazil
      • 11.4.6.2. Argentina
      • 11.4.6.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. GE Healthcare*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Jubilant Pharmova Limited (Jubilant Pharma Limited)
  • 13.3. Theragnostics Ltd.
  • 13.4. NuView Life Sciences
  • 13.5. Lantheus Holdings, Inc.
  • 13.6. CapVest Limited (Curium Pharma)
  • 13.7. Clarity Pharmaceuticals
  • 13.8. Cardinal Health, LLC
  • 13.9. Advanced Accelerator Applications
  • 13.10. ITM Isotopen Technologien Munchen AG

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us